Abstract
No public abstract is available from the verified source records.
Amanda Liesegang, Halle Powell, Anshini Jain, Helen Mohan, Jeanne Tie, Nicholas Clemons, Michael Michael, Glen Guerra, Alexander Heriot
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database
10.1016/s1470-2045(16)30500-9 · 2016
Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review
10.1016/j.critrevonc.2016.01.017 · 2016
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
10.1200/jco.2003.04.187 · 2003
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(20)30599-4 · 2021
Quality of life and minimal clinically important difference in colorectal cancer patients undergoing hyperthermic intraperitoneal chemotherapy: a large prospective cohort study
10.1245/s10434-025-18147-2 · 2025
Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis
10.1111/codi.15003 · 2020
Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1002/bjs5.50179 · 2019
Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis
10.1097/sla.0000000000001593 · 2016
Colic and rectal tumors with peritoneal metastases treated with cytoreductive surgery and HIPEC: one homogeneous condition or two different diseases? A systematic review and meta-analysis
10.1016/j.ejso.2019.06.020 · 2019
Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: a systematic review and meta-analysis
10.1016/j.ejso.2024.108474 · 2024
The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases
10.1016/j.ejso.2022.06.014 · 2022
Microsatellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
10.1245/s10434-021-11045-3 · 2022
Pelvic peritonectomy poorly affects outcomes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal metastases
10.1007/s11605-022-05501-y · 2023
The association of tumor laterality and survival after cytoreduction for colorectal carcinomatosis
10.1016/j.jss.2019.10.001 · 2020
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis
10.1097/sla.0b013e3182263933 · 2011
Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: italian multicenter study S.I.T.I.L.O
10.1016/j.ejso.2010.10.014 · 2011
Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients
10.1097/dcr.0000000000000149 · 2014
Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin
10.1016/j.ejso.2014.06.006 · 2014
Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology
10.1002/jso.23784 · 2015
Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands
10.1016/j.ejso.2015.01.018 · 2015
Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer
10.1245/s10434-015-4627-8 · 2016
What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures
10.1002/jso.24248 · 2016
Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases
10.1016/j.ejso.2016.03.014 · 2016
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort
10.1002/jso.24290 · 2016
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: long-term results at St george hospital, Australia
10.1111/ans.13152 · 2016
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in adolescent and young adults with peritoneal metastases
10.1245/s10434-016-5689-y · 2017
Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: what survival can we expect?
10.1016/j.ejca.2018.04.015 · 2018
Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a comparative study
10.1016/j.ejso.2018.08.012 · 2018
Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, observational study
10.1245/s10434-019-07294-y · 2019
Does primary tumor side matter in patients with metastatic Colon cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
10.1245/s10434-019-07255-5 · 2019
The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
10.1186/s12957-020-1784-4 · 2020
Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer
10.4251/wjgo.v12.i8.903 · 2020
Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study
10.1016/j.ejso.2020.04.018 · 2020
Patients with colorectal peritoneal metastases and high peritoneal cancer index May benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
10.1016/j.ejso.2020.07.039 · 2020
Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis
2021
Site of recurrence and survival after surgery for colorectal peritoneal metastasis
10.1093/jnci/djab001 · 2021
Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases
10.1016/j.ejso.2021.05.046 · 2021
Patterns and timing of recurrence following CRS and HIPEC in colorectal cancer peritoneal metastasis
10.1016/j.ejso.2022.07.019 · 2023
The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy
10.1016/j.ejso.2021.08.027 · 2022
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
10.1038/s41416-021-01620-6 · 2022
Association of inflammatory biomarkers with survival among patients with stage III Colon cancer
10.1001/jamaoncol.2022.6911 · doi-reference
Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials
10.1002/cam4.1126 · doi-reference
Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial
10.1016/s1470-2045(26)00085-9 · doi-reference
Role of circulating tumor DNA among patients with colorectal peritoneal metastases
10.1007/s12029-023-00959-8 · doi-reference
The utility of ctDNA in colorectal cancer with peritoneal metastases
10.1111/ans.18078 · doi-reference
Circulating tumor DNA testing for minimal residual disease and its application in colorectal cancer
10.3390/cells14030161 · doi-reference
Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin
10.1097/sla.0000000000002899 · doi-reference
Prognostic impact of primary side and RAS/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases
10.1245/s10434-020-09161-7 · doi-reference
Impact of primary tumor location and genomic alterations on survival following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for colorectal peritoneal metastases
10.1245/s10434-023-13463-x · doi-reference
Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC
10.1002/jso.26439 · doi-reference
Clinical and molecular features in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from colorectal cancer
10.1007/s11605-021-05073-3 · doi-reference
RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score
10.1245/s10434-019-07378-9 · doi-reference
A narrative review of what can HIPEC do
10.1016/j.ejso.2023.07.002 · doi-reference
Hyperthermic intraperitoneal chemotherapy in colorectal cancer
10.1093/bjsopen/zrae017 · doi-reference
Recurrence and survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for synchronous and metachronous peritoneal metastases of colorectal origin
10.3390/cancers16030631 · doi-reference
Extremely high peritoneal cancer index in colorectal peritoneal metastases demonstrates safety and overall survival benefit in selected patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy
10.1002/wjs.12080 · doi-reference
Actual 5-Year survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis of colorectal origin
10.1245/s10434-023-14608-8 · doi-reference
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan
10.1097/js9.0000000000000809 · doi-reference
Perioperative and oncological outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of rectal origin
10.1007/s11605-023-05833-3 · doi-reference
10.21873/anticanres.16530
10.21873/anticanres.16530 · doi-reference
RAS mutation status should not be used to predict outcome from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases
10.1245/s10434-022-12704-9 · doi-reference
Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland colorectal peritoneal metastases registry
10.1038/s41416-022-02037-5 · doi-reference
Long-term outcomes of elderly patients with peritoneal metastases of colorectal origin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
10.1016/j.suronc.2022.101848 · doi-reference
Peritoneal metastases of colorectal origin treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy: the efficiency of mitomycin C
10.1245/s10434-022-12221-9 · doi-reference
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre
10.1111/ans.17761 · doi-reference
Survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma
10.1245/s10434-022-11805-9 · doi-reference
In patients undergoing CRS/HIPEC for colorectal adenocarcinoma with peritoneal metastases, presence of ascites on computed tomography imaging is not a prognostic marker for survival
10.1245/s10434-022-11718-7 · doi-reference